AHA: Novartis hoping for second go at broader use with 'profound' Entresto subdata

It's been just a few weeks since Novartis' Entresto flopped a crucial heart failure study in what the drugmaker called a "narrow miss." Now, subanalyses from multiple studies show Entresto had a "profound effect" on some patients, giving Novartis hope for a second go.